Market Place
Sourcing Support
Texas biotech axes cancer pact, pins hopes on obesity
11 Oct 2024 //
FIERCE BIOTECH
Alaunos Therapeutics Announces Third Quarter 2023 Financial Results
14 Nov 2023 //
GLOBENEWSWIRE
Alaunos winds down sole cell therapy trial, cuts 60% of staff
16 Aug 2023 //
FIERCE BIOTECH
Alaunos Therapeutics Announces Second Quarter 2023 Financial Results
14 Aug 2023 //
GLOBENEWSWIRE
Alaunos Announces Presentation at the 2nd Hawaii Thoracic Malignancies
29 Jun 2023 //
GLOBENEWSWIRE
Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial
25 May 2023 //
GLOBENEWSWIRE
Alaunos Therapeutics Reports First Quarter 2023 Financial Results
10 May 2023 //
GLOBENEWSWIRE
Alaunos Therapeutics to Report 1Q 2023 Financial Results on May 10, 2023
03 May 2023 //
GLOBENEWSWIRE
Alaunos Therapeutics Announces Poster Presentation at the 2023 ASCO
26 Apr 2023 //
GLOBENEWSWIRE
Alaunos Therapeutics Appoints Dr. Robert J. Hofmeister to Board of Directors
30 Mar 2023 //
GLOBENEWSWIRE
Alaunos Therapeutics to Participate in Upcoming Investor Conferences in April
29 Mar 2023 //
GLOBENEWSWIRE
Alaunos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
07 Mar 2023 //
GLOBENEWSWIRE
Alaunos Therapeutics to Report Q4 and Full Year 2022 Financial Results
28 Feb 2023 //
GLOBENEWSWIRE
Alaunos Therapeutics Highlights Strategic Priorities and Anticipated Milestones
09 Jan 2023 //
GLOBENEWSWIRE
Alaunos Therapeutics Announces Pricing of Public Offering of Common Stock
29 Nov 2022 //
GLOBENEWSWIRE
Alaunos Therapeutics Announces Proposed Public Offering of Common Stock
28 Nov 2022 //
GLOBENEWSWIRE
Alaunos Therapeutics Reports Third Quarter 2022 Financial Results
14 Nov 2022 //
GLOBENEWSWIRE
Alaunos Therapeutics to Participate in Upcoming Investor Conferences in
07 Sep 2022 //
GLOBENEWSWIRE
Alaunos Announces Early Clinical Data Showing Objective Clinical Response
06 Sep 2022 //
GLOBENEWSWIRE
Alaunos to Present at the International Cancer Immunotherapy Conference
24 Aug 2022 //
GLOBENEWSWIRE
Alaunos Therapeutics Reports Second Quarter 2022 Financial Results
15 Aug 2022 //
GLOBENEWSWIRE
Alaunos Tx Appoints Abhishek Srivastava, Ph.D. as VP, Technical Operations
04 Aug 2022 //
GLOBENEWSWIRE
Alaunos Therapeutics to Present at the Jefferies Healthcare Conference
01 Jun 2022 //
GLOBENEWSWIRE
Alaunos to Present Trials in Progress Poster for its TCR-T Library PI/II trial
26 May 2022 //
GLOBENEWSWIRE
Alaunos Therapeutics Reports First Quarter 2022 Financial Results
16 May 2022 //
GLOBENEWSWIRE
Ziopharm Oncology Highlights Operational Progress & Rebrands to Alaunos Tx
26 Jan 2022 //
GLOBENEWSWIRE
Ziopharm Oncology Presents Preclinical Data Supporting TCR-T Library Approach
09 Nov 2021 //
GLOBENEWSWIRE
Ziopharm`s new CEO fires half of his workforce in first month
29 Sep 2021 //
ENDPTS
Ziopharm Oncology Announces Strategic Reduction in Workforce and Extension
27 Sep 2021 //
GLOBENEWSWIRE
Ziopharm finds new CEO; CFO transition at Lonza to take place in December
03 Sep 2021 //
ENDPTS
Ziopharm hires new CEO
30 Aug 2021 //
FIERCEBIOTECH
Ziopharm Oncology Appoints Kevin S. Boyle as CEO & Announces other Promotions
30 Aug 2021 //
GLOBENEWSWIRE
Ziopharm Oncology to Report Second Quarter Financial Results on August 9, 2021
26 Jul 2021 //
GLOBENEWSWIRE
Ziopharm Oncology Announces Clearance of Taiwan’s First IND of Non-viral CAR-T
21 Dec 2020 //
GLOBENEWSWIRE
Minority investor WaterMill succeeds in activist attack of Ziopharm
17 Dec 2020 //
ENDPTS
Minority investor WaterMill succeeds in activist attack of Ziopharm
17 Dec 2020 //
ENDPTS
Ziopharm Comments on Consent Solicitation Results
16 Dec 2020 //
PRESS RELEASE
Ziopharm drama continues with new letter from activist group; Alnylam, Centogene
08 Dec 2020 //
ENDPTS
Ziopharm`s activist drama continues as another board member member resigns
05 Dec 2020 //
ENDPTS
Ziopharm`s activist drama continues as another board member member resigns
04 Dec 2020 //
ENDPTS
Ziopharm Releases Investor Presentation to Enhance Shareholder Value
20 Nov 2020 //
BIOSPACE
Ziopharm Oncology Appoints Mary Thistle to Board of Directors
16 Nov 2020 //
PRESS RELEASE
Small cap immunotherapy player Ziopharm faces an activist attack, rebukes call
03 Nov 2020 //
ENDPTS
Ziopharm Oncology Granted Rare Pediatric Disease Designation
14 Sep 2020 //
GLOBENEWSWIRE
Ziopharm Oncology Doses First DIPG Patient in Ph 1/2 Trial of Controlled IL-12
08 Jul 2020 //
PRESS RELEASE
Ziopharm Oncology Completes Enrollment of Ph 2 Trial Libtayo® in Patients
22 Jun 2020 //
PRESS RELEASE
Ziopharm Oncology Presents Encouraging Clinical Data for Controlled IL-12
29 May 2020 //
PRESS RELEASE
Early survival data boost Ziopharm`s `controlled IL-12` immunotherapy
29 May 2020 //
ENDPTS
